semaglutide cardiovascular indication FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and death in adults with type 2 diabetes and chronic kidney disease SELECT Trial

Moniruzzaman, M

None of the other authors has any conflicts of interest, financial or otherwise, to disclose

Starting dose: what the research says versus what actually works The clinical trial starting dose for retatrutide is 1 mg subcutaneously once weekly

Shaking can cause mechanical damage to the peptide molecules, leading to aggregation and loss of potency

Another reason is delayed gastric emptying, Dr

When to seek medical advice: Persistent vomiting preventing adequate fluid intake Severe abdominal pain Signs of pancreatitis (severe upper abdominal pain radiating to the back) Symptoms of thyroid problems (lump in neck, hoarseness, difficulty swallowing) Any side effect that significantly impacts quality of life According to NICE guidance, treatment should be reviewed if HbA1c targets are not achieved or if side effects prove intolerable despite management strategies